AstraZeneca Pharmaceuticals, durvalumab, Imjudo, NSCLC, POSEIDON, tremelimumab
Tremelimumab is approved by FDA in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer
November 2022: The combination of tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), and platinum-based chemotherapy was approved by the Food and Drug Administration for adult pa..
durvalumab, hepatocellular carcinoma, tremelimumab
Tremelimumab is approved by FDA in combination with durvalumab for unresectable hepatocellular carcinoma
November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Efficacy was evaluat..
AstraZeneca UK Limited, durvalumab, Imfinzi, NCT03875235, TOPAZ-1
Durvalumab is approved for locally advanced or metastatic biliary tract cancer
November 2022: For adult patients with locally advanced or metastatic biliary tract cancer, the Food and Drug Administration has approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin (..